Genetic testing advances as insurers balk

Genetic testing offers real insights into how patients should be treated, but insurers have been reluctant to cover the cost of the tests. With a wave of new, more targeted biologics in the pipeline along with new tests to identify the people most likely to benefit from them, look for the issue to heat up considerably in the next few years.

- read the report on genetic testing from the San Jose Mercury News

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.